Logo of Robert Koch InstituteLogo of Robert Koch Institute
Publication Server of Robert Koch Instituteedoc
de|en
View Item 
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of edoc-ServerCommunity & CollectionTitleAuthorSubjectThis CollectionTitleAuthorSubject
PublishLoginRegisterHelp
StatisticsView Usage Statistics
All of edoc-ServerCommunity & CollectionTitleAuthorSubjectThis CollectionTitleAuthorSubject
PublishLoginRegisterHelp
StatisticsView Usage Statistics
View Item 
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
  • edoc-Server Home
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • View Item
2018-10-17Zeitschriftenartikel DOI: 10.25646/5998
What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea
Ronse, Maya
Saez, Almudena Mari
Gryseels, Charlotte
Bannister-Tyrrell, Melanie
Delamou, Alexandre
Guillard, Alain
Briki, Mustapha
Bigey, Frédéric
Haba, Nyankoye
van Griensven, Johan
Grietens, Koen Peeters
Introduction During the 2014 Ebola Virus Disease (EVD) epidemic, the Ebola-Tx trial evaluated the use of convalescent plasma (CP) in Guinea. The effectiveness of plasmapheresis trials depends on the recruitment of plasma donors. This paper describes what motivated or deterred EVD survivors to donate CP, providing insights for future plasmapheresis trials and epidemic preparedness. Methods This qualitative study, part of Ebola-Tx, researched and addressed emergent trial difficulties through interviewing, participant observation and focus group discussions. Sampling was theoretical and retroductive analysis was done in NVivo 10. Results Willingness or hesitance to participate in plasma donation depended on factors at the interface of pre-existing social dynamics; the impact of the disease and the consequent emergency response including the trial set-up. For volunteers, motivation to donate was mainly related to the feeling of social responsibility inspired by having survived EVD and to positive perceptions of plasmapheresis technology despite still unknown trial outcomes. Conversely, confidentiality concerns when volunteering due to stigmatization of survivors and perceived decrease in vital strength and in antibodies when donating, leading to fears of loss in protection against EVD, were main deterrents. The dynamic (dis)trust in Ebola Response Actors and in other survivors further determined willingness to participate and lead to the emergence/decline of rumours related to blood stealing and treatment effectiveness. Historic inter-ethnic relations in the health care setting further defined volunteering along socio-economic and ethnic lines. Finally, lack of follow-up and of dedicated care further impacted on motivation to volunteer. Conclusions Ebola-Tx was the first trial to solicit and evaluate blood-product donation as an experimental treatment on a large scale in Sub-Saharan Africa. An effective donation system requires directly engaging with emergent social barriers and providing an effective ethical response, including improved and transparent communication, effective follow-up after donation, assuring confidentiality and determining ethical incentives.
Files in this item
Thumbnail
What motivates Ebola survivors to donate plasma during an emergency clinical trial The case of Ebola-Tx in Guinea.pdf — Adobe PDF — 1.394 Mb
MD5: 8778e922367e25e265d596020fae6a7c
Cite
BibTeX
EndNote
RIS
(CC BY 3.0 DE) Namensnennung 3.0 Deutschland(CC BY 3.0 DE) Namensnennung 3.0 Deutschland
Details
Terms of Use Imprint Policy Data Privacy Statement Contact

The Robert Koch Institute is a Federal Institute

within the portfolio of the Federal Ministry of Health

© Robert Koch Institute

All rights reserved unless explicitly granted.

 
DOI
10.25646/5998
Permanent URL
http://dx.doi.org/10.25646/5998
HTML
<a href="http://dx.doi.org/10.25646/5998">http://dx.doi.org/10.25646/5998</a>